Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study
This prospective, noninterventional, open-label, multicentre, Belgian study assessed the prevalence of moderate to severe lower urinary tract symptoms (LUTS) in patients with locally advanced or metastatic prostate cancer scheduled to receive triptorelin therapy and its effects on LUTS were evaluate...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Prostate Cancer |
| Online Access: | http://dx.doi.org/10.1155/2015/978194 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548579585032192 |
|---|---|
| author | Alexandre Peltier Fouad Aoun Vincent De Ruyter Patrick Cabri Roland Van Velthoven |
| author_facet | Alexandre Peltier Fouad Aoun Vincent De Ruyter Patrick Cabri Roland Van Velthoven |
| author_sort | Alexandre Peltier |
| collection | DOAJ |
| description | This prospective, noninterventional, open-label, multicentre, Belgian study assessed the prevalence of moderate to severe lower urinary tract symptoms (LUTS) in patients with locally advanced or metastatic prostate cancer scheduled to receive triptorelin therapy and its effects on LUTS were evaluated focusing on symptom relief and changes in quality of life (QOL) related to urinary symptoms (November 2006 to May 2010). Inclusion criteria were age >18 years, histologically confirmed advanced or metastatic prostate cancer, and life expectancy ≥12 months. Exclusion criteria were treatment with any LHRH analogue within the last 6 months or any other investigational agent within the last 3 months before study entry. Patients who received one or more triptorelin doses and had one or more efficacy assessments were evaluated. In total, 325 patients were included with a median age of 74 years (50 to 95 years). Mean age at first diagnosis was 73±8 years. Moderate (IPSS 8–19) to severe (IPSS ≥ 20) LUTS were observed in 62% of patients. Triptorelin reduced LUTS severity. This improvement was perceived within the first 24 weeks of treatment and was maintained after 48 weeks. A decrease in PSA level was also observed. |
| format | Article |
| id | doaj-art-f20502a338014a97b78649e25069505b |
| institution | Kabale University |
| issn | 2090-3111 2090-312X |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Prostate Cancer |
| spelling | doaj-art-f20502a338014a97b78649e25069505b2025-02-03T06:13:52ZengWileyProstate Cancer2090-31112090-312X2015-01-01201510.1155/2015/978194978194Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT StudyAlexandre Peltier0Fouad Aoun1Vincent De Ruyter2Patrick Cabri3Roland Van Velthoven4Department of Urology, Jules Bordet Institute, 1000 Brussels, BelgiumDepartment of Urology, Jules Bordet Institute, 1000 Brussels, BelgiumIpsen NV, Guldensporenpark 87, 9820 Merelbeke, BelgiumIpsen NV, Guldensporenpark 87, 9820 Merelbeke, BelgiumDepartment of Urology, Jules Bordet Institute, 1000 Brussels, BelgiumThis prospective, noninterventional, open-label, multicentre, Belgian study assessed the prevalence of moderate to severe lower urinary tract symptoms (LUTS) in patients with locally advanced or metastatic prostate cancer scheduled to receive triptorelin therapy and its effects on LUTS were evaluated focusing on symptom relief and changes in quality of life (QOL) related to urinary symptoms (November 2006 to May 2010). Inclusion criteria were age >18 years, histologically confirmed advanced or metastatic prostate cancer, and life expectancy ≥12 months. Exclusion criteria were treatment with any LHRH analogue within the last 6 months or any other investigational agent within the last 3 months before study entry. Patients who received one or more triptorelin doses and had one or more efficacy assessments were evaluated. In total, 325 patients were included with a median age of 74 years (50 to 95 years). Mean age at first diagnosis was 73±8 years. Moderate (IPSS 8–19) to severe (IPSS ≥ 20) LUTS were observed in 62% of patients. Triptorelin reduced LUTS severity. This improvement was perceived within the first 24 weeks of treatment and was maintained after 48 weeks. A decrease in PSA level was also observed.http://dx.doi.org/10.1155/2015/978194 |
| spellingShingle | Alexandre Peltier Fouad Aoun Vincent De Ruyter Patrick Cabri Roland Van Velthoven Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study Prostate Cancer |
| title | Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study |
| title_full | Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study |
| title_fullStr | Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study |
| title_full_unstemmed | Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study |
| title_short | Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study |
| title_sort | triptorelin in the relief of lower urinary tract symptoms in advanced prostate cancer patients the result study |
| url | http://dx.doi.org/10.1155/2015/978194 |
| work_keys_str_mv | AT alexandrepeltier triptorelininthereliefoflowerurinarytractsymptomsinadvancedprostatecancerpatientstheresultstudy AT fouadaoun triptorelininthereliefoflowerurinarytractsymptomsinadvancedprostatecancerpatientstheresultstudy AT vincentderuyter triptorelininthereliefoflowerurinarytractsymptomsinadvancedprostatecancerpatientstheresultstudy AT patrickcabri triptorelininthereliefoflowerurinarytractsymptomsinadvancedprostatecancerpatientstheresultstudy AT rolandvanvelthoven triptorelininthereliefoflowerurinarytractsymptomsinadvancedprostatecancerpatientstheresultstudy |